Scientists create silk matrix for laboratory production of platelets | T cell therapy enters clinical testing for brain tumors | Bloodstream infection diagnostic tool developed for child cancer patients with fever
 
February 20, 2015
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP|FORWARD|ARCHIVE

Top Story
Scientists create silk matrix for laboratory production of platelets
Tufts University scientists have developed a silk-based, three-dimensional system for the culture of platelet-producing megakaryocytes, according to a study in the journal Blood. The method could be used to study platelet production, and it has the potential to be developed for clinical use, according to the researchers. NewKerala.com (India)/Indo-Asian News Service (2/19)
Share: LinkedInTwitterFacebookGoogle+Email
Science & Health
T cell therapy enters clinical testing for brain tumors
Scientists at the University of Pennsylvania's Abramson Cancer Center have begun a clinical study using T cells engineered to bind to the surface of cells that express the protein EGFRvIII for the treatment of brain cancer. A similar technique is being explored for possible use against leukemia. The study team's findings were reported in the journal Science Translational Medicine. United Press International (2/18)
Share: LinkedInTwitterFacebookGoogle+Email
Emerging Trends
Bloodstream infection diagnostic tool developed for child cancer patients with fever
A study the journal Pediatric Blood & Cancer has found that a prediction model for diagnosing bloodstream infections in febrile, non-neutropenic children with cancer was accurate. The findings were based on an analysis of data involving 463 patients with 932 febrile episodes and 91 cases of bloodstream infection. Healio (free registration)/Infectious Diseases in Children (2/19)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
Agilvax signs vaccine, immunotherapy pact with Humabs BioMed
Agilvax and Swiss firm Humabs BioMed agreed to jointly develop targeted vaccines and immunotherapies for unmet medical conditions using antibodies derived from chronic and infectious disease survivors. The antibodies will be provided by Humabs. Using the antibodies "ensures the creation of vaccines and immunotherapies that produce strong and precise immune responses, and ultimately improves health outcomes and patient well-being," said Agilvax President and CEO Federica Pericle. Pharmaceutical Business Review Online (2/18)
Share: LinkedInTwitterFacebookGoogle+Email
Teva enters license agreement with Eagle Pharma for experimental leukemia therapy
Teva Pharmaceutical Industries has signed an exclusive licensing agreement with Eagle Pharmaceuticals for EP-3102, a bendamustine hydrochloride rapid infusion product for patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva will handle promotion and distribution in the U.S., while Eagle will be responsible for securing all regulatory approvals. RTT News (2/17)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
FDA proposes adverse-event reporting guidance for cellular, tissue products
The FDA has released new draft guidelines describing the kinds of adverse events related to the use of human cells, tissues, and cellular and tissue-based products that should be reported to the FDA, and how establishments should report the events. The report should be filed by the establishment that makes HCT/Ps available for distribution, and it should be done within 15 days of the discovery of the event, the agency said. Regulatory Focus (2/19)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
Reminder: 2nd edition of Hematopoietic Stem Cell Transplantation Handbook available for purchase
AABB has published the 2nd edition of Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians. The new edition provides relevant information on all areas of hematopoietic stem cell transplantation including indications for transplantation; donor and patient evaluation; management of immunosuppressive therapy; and evaluation and management of the most common complications during HSCT. The content has been updated and reorganized so readers can find topics that interest them more easily. In addition, chapters have been added on nonmalignant diseases, haploidentical transplants, photopheresis, financial considerations and iron overload. This book can be purchased in the AABB Marketplace.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Reference Technologist (CLS)LifeStreamSan Bernardino, CA
Volunteer CoordinatorAABBBethesda, MD
Regulatory Affairs ManagerAABBMD
Clinical Laboratory ScientistEisenhower Medical CenterRancho Mirage, CA
Supervisory Medical OfficerNational Institutes of HealthBethesda, MD
Click here to view more job listings.
 
SmartQuote
Your present circumstances don't determine where you can go; they merely determine where you start."
-- Nido Qubein,
businessman and motivational speaker
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising:  Meryl Harold
  P: 202.407.7828
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information